The city of Baltimore, Maryland, currently has 3 active clinical trials seeking participants for Hepatitis C research studies.
The HOPE Study: Characterizing Patients With Hepatitis B and C
Recruiting
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections w... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/02/2024
Locations: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland
Conditions: Hepatitis B, Chronic, Hepatitis C
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
Recruiting
The investigators will conduct a randomized controlled clinical trial study in an urban emergency department in Baltimore to determine the impact of an educational app which is based on Leventhal's Common-Sense Model of Illness Representations framework, on HCV-infected ED patient's hepatitis C virus (HCV) health belief and knowledge as well as the downstream outcomes of the HCV Continuum of Care (linkage to care rate, initiation of HCV antiviral treatment, and sustained virologic response). Fir... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/14/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Hepatitis C
Rapid HCV Treatment Access for Persons Who Use Drugs
Recruiting
This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP). Participants will be randomized into one of two treatment groups: Test and treat plus peer-mentors: This treatment group will be offered 8 weeks of glecaprevir/pibrentasvir (an FDA approved HCV treatment) within days of HCV diagnosis at the OTP. Participants in this group will receive treatme... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/08/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Hepatitis C Virus Infection, Response to Therapy of